1 Unequal access to diagnosis of myalgic encephalomyelitis in England

2

3 Gemma L. Samms¹ and Chris P. Ponting^{1*}

4 * Corresponding Author

¹ MRC Human Genetics Unit, The University of Edinburgh, Edinburgh, Scotland, EH4 2XU, UK

6

7 Abstract

8 Background

9 People with Myalgic Encephalomyelitis (ME/CFS; sometimes referred to as chronic fatigue 10 syndrome) experience very poor health-related quality of life and only rarely recover. ME/CFS has 11 no curative treatment and no single diagnostic test. Public health and policy decisions relevant to 12 ME/CFS require knowledge of its prevalence and barriers to diagnosis. However, people with 13 ME/CFS report lengthy diagnostic delays and widespread misunderstanding of their symptoms. 14 Published prevalence estimates vary greatly by country, gender, age and ethnicity.

15 Methods

Hospital Episode Statistics data is routinely collected by the NHS in England together with patient
age, gender and ethnicity. This data, downloaded from the Feasibility Self-Service of NHS DigiTrials,
was used to stratify individuals with the ICD-10 code that best reflects ME/CFS symptoms (G93.3;
"Postviral fatigue syndrome") according to their age, self-reported gender and ethnicity, General
Practice and NHS England Integrated Care Board (ICB).

21 Results

In all, 100,055 people in England had been diagnosed with ME/CFS (ICD-10:G93.3) between April 1
1989 and October 7 2023, 0.16% of all registered patients. Of these, 79,445 were females and
20,590 males, a female-to-male ratio of 3.88:1. Female relative to male prevalence peaked at about
6-to-1 in individuals' fourth and fifth decades of life. Prevalence varied widely across the 42 ICBs:
0.086%-0.82% for females and 0.024%-0.21% for males. White individuals were approximately 5-fold

27 more likely to be diagnosed with ME/CFS than others; black, Asian or Chinese ethnicities are 28 associated with particularly low rates of ME/CFS diagnoses. This ethnicity bias is stronger than for 29 other common diseases. Among active English GP practices, 176 (3%) had no registered ME/CFS 30 patients. Eight ICBs (19%) each contained fewer than 8 other-than-white individuals with a G93.3 31 code despite their registers containing a total of 293,770 other-than-white patients.

32 Conclusion

Those who are disproportionately undiagnosed with ME/CFS are other-than-white ethnic groups, older females (>60y), older males (>80y), and people living in areas of multiple deprivation. The lifetime prevalence of ME/CFS for English females and males may be as high as 0.92% and 0.25%, respectively, or approximately 390,000 UK individuals overall. This improved estimate of ME/CFS prevalence allows more accurate assessment of the socioeconomic and disease burden imposed by ME/CFS.

39

40 Introduction.

41

42 At the population scale, estimates of disease morbidity and prevalence inform public health and 43 policy decisions; for individuals, accurate diagnosis informs symptom management and treatment. 44 Myalgic Encephalomyelitis (ME; sometimes referred to as Chronic Fatigue Syndrome [1]) is a chronic 45 multi-system disorder resulting in very poor health-related quality of life and from which patients 46 only rarely recover [2][3]. ME/CFS is relatively common [4]: prevalence estimates in the UK or the 47 USA range from 0.2%-0.4% [5][6][7], depending on case definition. A meta-analysis of 56 data sets 48 covering 1.1m individuals indicated an even higher prevalence, at 0.89% (95% CI: 0.60-1.33). 49 However, this study's criteria did not require post-exertional malaise (PEM), the worsening or new 50 appearance of symptoms after previously tolerated physical or cognitive exertion, which 51 nevertheless is a primary symptom of ME/CFS [8]. More recently, the USA National Health Interview

52 Survey reported 1.3% of adults having a ME/CFS diagnosis and ongoing symptoms during 2021-2022

53 [9], and the All of Us study report 0.46% of their USA cohort with ME/CFS (ICD9CM-780.71; [10]).

54

55 ME/CFS diagnosis varies firstly by sex, with women diagnosed two- to five-times more often than 56 men and also tending to report more severe symptoms [11][9]. Diagnosis also may vary by ethnicity, 57 although studies disagree on which group is more frequently diagnosed: African Americans and 58 Native Americans [12], or White or Black (non-Hispanic) individuals [9], or African American and 59 Latinx youth [13][7].

60

In this study, we report Hospital Episode Statistics (HES) data for NHS Hospitals in England, specifically the ICD-10 code G93.3 ("Postviral fatigue syndrome") which is the code that best reflects ME/CFS symptoms. Rather than being General Practice (GP) data, and rather than being UK-wide, the data is HES- and England-specific, and hence does not report UK-wide prevalence. Nevertheless, when stratified by age, self-reported ethnicity and sex the data reveals substantial population variation in ME/CFS diagnosis.

67

68 Results

69

70 Prevalence by age, deprivation and sex

On 7 October 2023, 100,055 people had an electronic health record code for ME/CFS across the 42 NHS England Integrated Care Boards (ICBs). These are among 62,782,175 people (0.16%) with a valid NHS number, who were registered with a GP and were not deceased. This information was supplied by the Feasibility Self-Service of NHS DigiTrials [14] who provide Hospital Episode Statistics that are routinely collected by the NHS in England and held by NHS England. In all, 79,445 (0.25% of 31,297,675) females and 20,590 (0.065% of 31,481,510) males were associated with the ICD10 G93.3 code, a female-to-male (F/M) ratio of 3.88:1; 20 people with ME/CFS did not specify their gender.

78 F/M ratio exceeded 3.3 across all of the 42 ICBs (range 3.3-4.5) (Figure 1A).

79

Across the ICBS, female or male prevalence varied by an order of magnitude: 0.086%-0.82% and 0.024%-0.21%, respectively. Cornwall and the Isles of Scilly had the highest prevalence for each gender, and North West or North East London the lowest for females or males, respectively (**Figure 1B**).

84

Point prevalence of ME/CFS varied greatly across lifespan, peaking at about 50 years of age for females and over a decade later for males (**Figure 2A**). In individuals' fourth and fifth decades the F/M ratio peaked at an exceptionally large value, approximately 6-to-1.

88

ME/CFS prevalence varied 1.5-fold by deprivation assessed by the Index of Multiple Deprivation (IMD). The IMD is a measure of relative deprivation for small areas in England [15] combining seven domains: income; employment; education, skills and training; health and disability; crime; housing and services; and the living environment. Each small area has been ranked and divided into tenths ('deciles') from the most deprived (decile 1) to the least deprived (decile 10). ME/CFS prevalence was lowest for those living in areas among the three most deprived deciles (**Figure 2B**).

95

96 Prevalence by ethnicity

Ethnic groups showed unexpectedly large variation in ME/CFS prevalence. Specifically, white
prevalence was 4.9-fold higher than other-than-white prevalence (0.24% vs 0.049%, respectively).
This finding was observed across all ICBs for both sexes (Figure 1B). Variation of ME/CFS prevalence

100 by IMD deciles was similar between white and other-than-white ethnicities (Figure 2C).

101

ME/CFS prevalence of other-than-white British individuals was between one-tenth and one-third that for white British. Those with Chinese, Asian/Asian British or black/black British ethnicity were 11%, 11%-19%, or 10%-35%, respectively, less likely to be diagnosed with ME/CFS (**Figure 3A**). The low prevalence of ME/CFS for other-than-white ethnicity categories is more profound than for other diseases, for example fibromyalgia and clinical depression (**Figure 3A**).

107

Eight ICBs each contained fewer than 8 other-than-white individuals with a G93.3 code (≤0.0027%
for 293,770 other-than-white individuals). These 8 ICBs were Dorset; Gloucestershire; Herefordshire
and Worcestershire; Lincolnshire; Northamptonshire; Shropshire, Telford and Wrekin; Somerset;
and, Staffordshire and Stoke-on-Trent.

112

In summary, ME/CFS diagnosis in England is highest among older, white females, and lowest among
 younger other-than-white males; the variation is 50-fold between these three categories (Figure 3B).

115

116 Prevalence per GP practice

117 Lastly, we considered 6,113 English GP practices with at least 2,500 registered patients which each, 118 given the national prevalence of 0.16% (above), would be expected to have 4 or more ME/CFS 119 patients registered. Two-thirds of these practices (4,061; 66%) had 8 or more registered patients 120 with ME/CFS and 97% (5,937) reported at least one individual with ME/CFS. Of the remaining 121 practices, 176 (3%) had no registered ME/CFS patients recorded in HES despite being operational 122 and having a median of 4,765 registered patients (range 2,665-12,170), a total population of 123 917,570. These 176 practices are disproportionately located in the most deprived areas of England 124 (Figure 4).

125

126 Discussion

127 Across England, ME/CFS diagnosis varies 50-fold, with considerable variation by gender, age, 128 ethnicity, and location (Figure 3B; Figure 1; Figure 2C). Female-bias contributes about 4-fold, mid-129 way among previous values for single-country or international ME/CFS cohorts (1.5-6 fold 130 [11][1][16][17][18][19][20]). This wide variation may result, in part, from cohorts sampling from 131 different age ranges (Figure 2A). Young (<40y) or old (>40y) age contributes ~3-fold to ME/CFS 132 prevalence variation (Figure 2A; Figure 3B), reflecting an accumulation of ME/CFS diagnoses over 133 adult life. Decreased ME/CFS female prevalence in later life (>60y; Figure 1B) cannot be due to 134 recovery, as records are deleted only rarely, or increased mortality [21] but could reflect historically 135 low levels of diagnoses. The 20y difference between the highest male (ages 71-80y) and highest 136 female (ages 51-60y) prevalence is puzzling although it may reflect gender-specific historical 137 variation in ME/CFS diagnosis. Older females (>60y) and males (>80y) are less likely to be coded with 138 ME/CFS in their hospital records (Figure 2A). However, note that if they were diagnosed before 1st 139 April 1989 and were not since re-coded in their hospital records, their diagnosis will be missing from 140 the data we analysed.

141 White versus other-than-white ethnicity accounts for a further ~5-fold variation (Figure 3B), with 142 some ethnicities (e.g. black, Asian or Chinese ancestry) associated with particularly low rates of 143 ME/CFS diagnoses (Figure 3A). This ethnicity bias is stronger than for other common diseases such 144 as dementia, ischaemic heart disease, clinical depression, and fibromyalgia [22](Figure 3A). The bias 145 is unlikely to reflect genetic differences [23], or to unequal access to primary care because other-146 than-white individuals are not less likely to visit GP services [24]. Rather it is likely due to fewer 147 hospital visits by people of East Asian ancestry [24] and to wider social and economical health 148 factors [25]. Barriers to diagnosing and managing ME/CFS in other-than-white groups have 149 previously been recognised [26]. These will need to be overcome if there is to be equitable access to 150 ME/CFS diagnosis and healthcare.

Age-at-ME/CFS diagnosis is highly variable, especially for paediatric ME/CFS cases: this study identified few <18y old ME/CFS cases in England (0.010% for both genders combined; **Figure 2A**), consistent with the UK overall [11]. In other countries, however, paediatric prevalence of ME/CFS is much higher [27], e.g., 0.75% in a USA community cohort [13]; 26% of Norwegian ME/CFS patients were younger than 20y old [17]. Paediatric ME/CFS referral services in England and the rest of the UK are limited [28].

A strength of this study is that it captures all ME/CFS diagnoses given the G93.3 ICD-10 code during admissions, outpatient appointments and historical Accident and Emergency attendances at English NHS hospitals up to October 2023. It is over two orders of magnitude larger in scale than a primary care study of 3 English areas [5] whose prevalence estimate (0.11-0.20%) is comparable to this study's G93.3 prevalence (0.16%). A weakness is that those whose ME/CFS was diagnosed in primary care will only have been included if their G93.3 code was subsequently added to the HES data in secondary care.

164 With this study's data, we can now estimate the number of people in the UK who would have a 165 ME/CFS diagnosis (i.e. the G93.3 code) if there were minimal social and healthcare barriers to 166 diagnosis. For this, we used the maximal ME/CFS prevalences for white females and males (0.92% 167 and 0.25%, respectively), which are for NHS Cornwall and Isles of Scilly (Figure 1B). This ICB would be 168 expected to have the highest fraction of diagnosed ME/CFS patients as it has the oldest population 169 (average ~45y [females] and ~44y [males]), the highest F/M ratio (1.04) and, most strikingly, the 170 lowest other-than-white population (2.0%). If all 67 million UK citizens [29] were to have a lifetime 171 prevalence matching the point prevalence of NHS Cornwall and Isles of Scilly then 83,750 males and 172 308,200 females would be given a G93.3 ME/CFS diagnosis in their lifetime. These are lower bound 173 estimates because no account is taken of those in NHS Cornwall and Isles of Scilly who have yet to 174 receive a ME/CFS diagnosis. This total of 391,950 would be a 57% increase over a current prevalence 175 estimate of 250,000 [30]. Even if half of these do not meet more stringent diagnostic criteria for ME/CFS (as previously [31][32]), then this reduction could be offset by those diagnosed in primary care, but not coded in the HES data analysed in this study. In summary, we suggest that the 2023 UK lifetime prevalence of ME/CFS diagnosed using stringent criteria is approximately 300,000 for females and 85,000 for males (i.e., 0.92% and 0.25%, respectively).

180 In summary, these results reveal deficiencies in ME/CFS diagnosis across different groups in England. 181 To address these deficiencies, improved training of medical professionals should be available [33] 182 and research into identifying accurate diagnostic tests should be prioritised. Even when diagnosed, 183 there is no curative therapy for ME/CFS, only symptom management [33] Nevertheless, an 184 individual's ME/CFS diagnosis provides considerable value as it: (i) counters the delegitimization of 185 problems often experienced by ME/CFS patients [34][35], (ii) improves patient/professional 186 relationships, (iii) facilitates symptom management, (iv) enables application for disability benefits, 187 (v) assists recruitment to future clinical trials of potentially effective treatments, and (vi) helps 188 individuals to join supportive and informative patient communities.

189

190 Methods

The NHS DigiTrials Feasibility Self-Service (England only [14]) returned all ME/CFS diagnoses since 1st 191 192 April 1989, stratified by ICB, sex, age and self-reported ethnicity (accessed on 7-10 October 2023). 193 For each stratum, NHS DigiTrials data is rounded: counts equal to or exceeding 8 are rounded to the 194 nearest increment of 5; counts equal to or less than 7 were not provided and so were set to zero. 195 Data was for 62,782,175 individuals who are alive, have a valid NHS number and are registered with 196 a GP in England. Data also includes those who previously met these criteria but are no longer 197 residing in England [36]. Individuals are recorded once without duplicates. NHS DigiTrials returns 198 data derived from Hospital Episode Statistics (HES) for admissions, outpatient appointments and 199 historical Accident and Emergency attendances [36]. HES are linked via the patients' registered GP 200 practice, and these 6,119 GP practices are linked to 42 ICBs. 6 GP practices were not considered further because they had fewer than 2,500 registered patients. HES data is updated monthly, on the second day of each month. Personal demographic data is updated daily. Patients with multiple diagnoses of the same type/code are counted only once, specifically the latest occurrence. As in other studies (e.g., [17]) we consider G93.3 to be the ICD-10 code that best reflects ME/CFS symptoms.

206

207 We apply the UK Government's recommendations for describing ethnicity [37]. NHS DigiTrials uses 208 self-reported ethnicity as classified in the 2001 census. 'White' includes 'white British', 'white Irish' 209 and 'Any other white background'. 'Other than white' includes any other ethnic group; Asian or 210 Asian British - Any other Asian background; Asian or Asian British - Bangladeshi; Asian or Asian 211 British - Indian; Asian or Asian British - Pakistani; Black or Black British - African; Black or Black British 212 - Any other Black background; Black or Black British - Caribbean; Chinese; Mixed - Any other mixed 213 background; Mixed - White & Asian; Mixed - White & Black African; Mixed - White & Black 214 Caribbean). These two categories exclude those whose ancestry is ambiguous (i.e. 'not stated' or 215 'unknown'). Individuals whose ethnicity was 'not stated' or 'unknown' were included for non-216 ethnicity related analyses.

217

218 NHS DigiTrials provided numbers of ME/CFS patients coded with G93.3 in active GP practices in 219 England. For each GP practice these were indicated as between 1 and 7, or if equal to or above 8, 220 provided to the nearest increment of 5. Active practices were those without a closed date, with 221 \geq 2,500 registered patients, whose status is 'active' and 'operational' (similarly for its related ICB), 222 and with a valid postcode.

For Figure 2B and 2C patients were partitioned into deciles of English indices of deprivation (IMD; 2019) by their address (1=most deprived, 10=least deprived). For Figure 4, English indices of deprivation for GP practices were acquired using their postcodes [15].

226

227 Acknowledgements

228 NHS data is copyright © 2022, NHS England, re-used with the permission of NHS England. All rights 229 reserved. Access to this data was provided by NHS DigiTrials and the Feasibility Self-Service. Funding 230 for access was provided by the National Institute for Health and Care Research (NIHR) and Medical 231 Research Council (MRC), grant number MC_PC_20005. GLS was funded by a PhD studentship from 232 ME Research UK. We would like to thank Profs Sarah Wild and Raj Bhopal (University of Edinburgh) 233 and Simon McGrath for helpful discussions, and Dr Diana Garcia (University of Edinburgh) for 234 assistance in acquiring the NHS DigiTrials data.

235

236 Figure Legends.

Figure 1. Diagnoses across 42 English Integrated Care Boards (ICB). (A) Ratios of female-to-male
ME/CFS diagnoses (ICD-10:G93.3 codes) by ICB. (B) Point prevalence of males (left) or females (right)
with ME/CFS stratified by ethnicity: either white or other-than-white. Blue: white females; Orange:
Other-than-white Females; Green: white Males; Purple: Other-than-white Males.

241

Figure 2. ME/CFS diagnoses by age or deprivation. (A) Ages of females or males with ME/CFS diagnoses in England (light blue: females; dark blue: males; black: overall ratio) as of 7th October 2023. The female-to-male ME/CFS diagnosis ratios for every age decade are shown in boxes. (B) ME/CFS patients partitioned by Indices of multiple deprivation (IMD) in deciles. (C) As (B), but separated by self-reported white or other-than-white ethnicities.

247

Figure 3. Relative prevalence of ME/CFS and other diseases stratified by ethnic group, age and gender. (A) Prevalence of ME/CFS (ICD-10:G93.3), Fibromyalgia (ICD-10: M79.7), Rheumatoid arthritis (M05.3, M05.8, M05.9, M06.0, M06.8, M06.9 or M08.0), clinical depression (F32 or F33 codes), Irritable Bowel Syndrome (K58.0 or K58.9), Coeliac Disease (K90.0), or Multiple Sclerosis (G35) for self-reported ethnicities relative to 'white British'. Codes were downloaded from NHS

- 253 DIgiTrials on 8th October 2023. (B) ME/CFS prevalence for female or male groups, of younger or
- older age, and of white or other-than-white ethnicity, relative to young (<40y old) white males
- 255 (normalised to 1.0).
- 256
- 257 Figure 4. English GP practices. Numbers of active GP practices without registered ME/CFS patients
- 258 recorded in HES stratified by indices of multiple deprivation.
- 259

260 References

- 261 1. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome;
- 262 Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic
- 263 Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. 2015.
- 264 2. Falk Hvidberg M, Brinth LS, Olesen A V, Petersen KD, Ehlers L. The Health-Related Quality of Life
 265 for Patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS). PLoS One.
 2015;10:e0132421.
- 267 3. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome.
 268 Occup Med (Lond). 2005;55:20–31.
- 269 4. Valdez AR, Hancock EE, Adebayo S, Kiernicki DJ, Proskauer D, Attewell JR, et al. Estimating
- Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine
 Learning. Front Pediatr. 2018;6:412.
- 5. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, et al. Prevalence of myalgic
 encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated crosssectional study in primary care. BMC Med. 2011;9:91.
- 6. Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, Randall B, et al. Prevalence and
- incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med. 2003;163:1530–6.
- 7. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys A V., Taylor RR, et al. A CommunityBased Study of Chronic Fatigue Syndrome. JAMA Intern Med. 1999;159:2129–37.
- 279 8. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a

comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study
 Group. Ann Intern Med. 1994;121:953–9.

- 9. Vahratian A, Lin J-MS, Bertolli J, Unger ER. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- in Adults: United States, 2021–2022. NCHS Data Brief No. 488. 2023.
- 284 https://www.cdc.gov/nchs/products/databriefs/db488.htm. Accessed 31 Jan 2024.
- 285 10. All of Us Research Hub myalgic encephalomyelitis. 2024.
- 286 https://databrowser.researchallofus.org/ehr/conditions/myalgic%20encephalomyelitis. Accessed 31
- 287 Jan 2024.

- 11. Bretherick AD, McGrath SJ, Devereux-Cooke A, Leary S, Northwood E, Redshaw A, et al. Typing
 myalgic encephalomyelitis by infection at onset: A DecodeME study. NIHR open research. 2023;3:20.
- 290 12. Dinos S, Khoshaba B, Ashby D, White PD, Nazroo J, Wessely S, et al. A systematic review of
- chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. Int J
 Epidemiol. 2009;38:1554–70.
- 293 13. Jason LA, Katz BZ, Sunnquist M, Torres C, Cotler J, Bhatia S. The Prevalence of Pediatric Myalgic
- 294 Encephalomyelitis/Chronic Fatigue Syndrome in a Community-Based Sample. Child Youth Care
- 295 Forum. 2020;49:563–79.
- 296 14. NHS DigiTrials. 2024. https://digital.nhs.uk/services/nhs-digitrials. Accessed 31 Jan 2024.
- 297 15. English indices of deprivation 2019. 2019. https://www.gov.uk/government/statistics/english298 indices-of-deprivation-2019. Accessed 31 Jan 2024.
- 299 16. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Trends in the incidence of chronic fatigue
- syndrome and fibromyalgia in the UK, 2001-2013: a Clinical Practice Research Datalink study. J R Soc
 Med. 2017;110:231-44.
- 302 17. Bakken IJ, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, et al. Two age peaks in the
 303 incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study
 304 from Norway 2008-2012. BMC Med. 2014;12:167.
- 18. Knight S, Harvey A, Lubitz L, Rowe K, Reveley C, Veit F, et al. Paediatric chronic fatigue syndrome:
 complex presentations and protracted time to diagnosis. J Paediatr Child Health. 2013;49:919–24.
- 307 19. Orji N, Campbell JA, Wills K, Hensher M, Palmer AJ, Rogerson M, et al. Prevalence of myalgic
 308 encephalomyelitis/chronic fatigue syndrome (ME/CFS) in Australian primary care patients: only part
 309 of the story? BMC Public Health. 2022;22:1516.
- 20. Pheby D, Lacerda E, Nacul L, Drachler M de L, Campion P, Howe A, et al. A Disease Register for
 ME/CFS: Report of a Pilot Study. BMC Res Notes. 2011;4:139.
- 312 21. Roberts E, Wessely S, Chalder T, Chang C-K, Hotopf M. Mortality of people with chronic fatigue
- 313 syndrome: a retrospective cohort study in England and Wales from the South London and Maudsley
- 314 NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Clinical Record Interactive Search
- 315 (CRIS) Register. Lancet. 2016;387:1638–43.
- 316 22. Mortality from leading causes of death by ethnic group, England and Wales: 2012 to 2019. 2021.
- 317 https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/article
- s/mortalityfromleadingcausesofdeathbyethnicgroupenglandandwales/2012to2019. Accessed 31 Jan
 2024.
- 320 23. Birney E, Inouye M, Raff J, Rutherford A, Scally A. The language of race, ethnicity, and ancestry in
 human genetic research. 2021.
- 322 24. Nazroo JY, Falaschetti E, Pierce M, Primatesta P. Ethnic inequalities in access to and outcomes of
- healthcare: analysis of the Health Survey for England. J Epidemiol Community Health (1978).
- 324 2009;63:1022-7.
- 325 25. Chouhan K, Nazroo J. Health inequalities. In: Byrne B, Alexander C, Khan O, Nazroo J, Shankley W,
- editors. Ethnicity, Race and Inequality in the UK. Bristol: Bristol University Press; 2020. p. 73–92.

- 327 26. Bayliss K, Riste L, Fisher L, Wearden A, Peters S, Lovell K, et al. Diagnosis and management of
- 328 chronic fatigue syndrome/myalgic encephalitis in black and minority ethnic people: a qualitative
- 329 study. Prim Health Care Res Dev. 2014;15:143–55.
- 330 27. Lim E-J, Ahn Y-C, Jang E-S, Lee S-W, Lee S-H, Son C-G. Systematic review and meta-analysis of the
- 331 prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med.
- 332 2020;18:100.
- 28. Diagnosis of ME/CFS. The importance of having an early and accurate diagnosis. 2022.
- 29. Population estimates for the UK, England, Wales, Scotland and Northern Ireland: mid-2021.
 2022.
- 336 https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationesti
- 337 mates/bulletins/annualmidyearpopulationestimates/mid2021. Accessed 31 Jan 2024.
- 338 30. National Institute for Health and Care Excellence. Myalgic encephalomyelitis (or
- encephalopathy)/chronic fatigue syndrome: diagnosis and management. 2021.
- 340 31. Newton JL, Mabillard H, Scott A, Hoad A, Spickett G. The Newcastle NHS Chronic Fatigue
- 341 Syndrome Service: not all fatigue is the same. J R Coll Physicians Edinb. 2010;40:304–7.
- 342 32. Devasahayam A, Lawn T, Murphy M, White PD. Alternative diagnoses to chronic fatigue
- syndrome in referrals to a specialist service: service evaluation survey. JRSM Short Rep. 2012;3:4.
- 33. Muirhead N, Muirhead J, Lavery G, Marsh B. Medical School Education on Myalgic
 Encephalomyelitis. Medicina (Kaunas). 2021;57.
- 346 34. Froehlich L, Hattesohl DB, Cotler J, Jason LA, Scheibenbogen C, Behrends U. Causal attributions
- and perceived stigma for myalgic encephalomyelitis/chronic fatigue syndrome. J Health Psychol.
 2022;27:2291–304.
- 349 35. Asbring P, Närvänen A-L. Women's experiences of stigma in relation to chronic fatigue syndrome
 and fibromyalgia. Qual Health Res. 2002;12:148–60.
- 36. Hospital Episode Statistics (HES). 2023. https://digital.nhs.uk/data-and-information/data-tools and-services/data-services/hospital-episode-statistics. Accessed 31 Jan 2024.
- 353 37. Writing about ethnicity. 2021. https://www.ethnicity-facts-figures.service.gov.uk/style-
- 354 guide/writing-about-ethnicity/. Accessed 31 Jan 2024.
- 355

Figure 1



0.0% 0.2% 0.0% 0.2% 0.4% 0.6% 0.8% 1.0%

Figure 2





Figure 3B





Figure 4

Figure 3A

